Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

Inclusion Criteria:

• Participants' body weight must be >= 40 kg at Baseline.

• Confirmed diagnosis of CD for at least 3 months prior to Baseline. Documentation ofbiopsy results consistent with the diagnosis of CD as assessed by the Investigatormust be available.

• CDAI >= 220 at Baseline.

• Endoscopic evidence of mucosal inflammation as documented by an SES-CD of >= 6 forileocolonic or colonic disease or SES-CD of >= 4 for isolated ileal disease. Alleligible scores exclude the presence of narrowing component and are determined by areader.

• Participants must demonstrate intolerance or inadequate response to conventionaltherapies (OUS) and/or TaTs. TaTs include biologics and/or targeted small molecules.

Exclusion Criteria:

• Participant who demonstrated intolerance to p19 inhibitors, including risankizumab.

• Participant who received any investigational TaT (or TaT that becomes approvedduring the conduct of the study) within 30 days or 5 half-lives prior to Baseline,whichever is longer. Note: If there is documentation of an undetectable (or belowthe lower limit of quantification/quantitation) drug level measured by acommercially available assay for any of the approved biologics above, there is nominimum washout prior to Baseline.

• Participant who have any of the following: Current diagnosis of UC or indeterminatecolitis. Currently known complications of CD such as: Current ostomy or ileoanalpouch; Current short gut or short bowel syndrome; Surgical bowel resection withinthe past 3 months prior to Baseline.